EDITAS MEDICINE, INC. Debt Securities, Available-for-sale, Amortized Cost
EDITAS MEDICINE, INC. (EDIT) had Debt Securities, Available-for-sale, Amortized Cost of $211.65 million as of 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Notes › Credit Losses
us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis · last filed 2026-08-05
- 2026-06-30: Debt Securities, Available-for-sale, Amortized Cost $211.65M.
- 2026-03-31: Debt Securities, Available-for-sale, Amortized Cost $123.65M.
- 2025-12-31: Debt Securities, Available-for-sale, Amortized Cost $146.65M.
- 2025-09-30: Debt Securities, Available-for-sale, Amortized Cost $165.65M.
| Period end | Debt Securities, Available-for-sale, Amortized Cost |
|---|---|
| 2026-06-30 | $211.65M 10-Q · filed 2026-08-05 |
| 2026-03-31 | $123.65M 10-Q · filed 2026-05-05 |
| 2025-12-31 | $146.65M 10-Q · filed 2026-08-05 |
| 2025-09-30 | $165.65M 10-Q · filed 2025-11-10 |
| 2025-06-30 | $178.49M 10-Q · filed 2025-08-12 |
| 2025-03-31 | $220.88M 10-Q · filed 2025-05-12 |
| 2024-12-31 | $269.64M 10-K · filed 2026-03-09 |
| 2024-09-30 | $264.57M 10-Q · filed 2024-11-04 |
| 2024-06-30 | $318.75M 10-Q · filed 2024-08-07 |
| 2024-03-31 | $377.10M 10-Q · filed 2024-05-08 |
| 2023-12-31 | $426.94M 10-K · filed 2025-03-05 |
| 2023-09-30 | $447.87M 10-Q · filed 2023-11-03 |
| 2023-06-30 | $482.32M 10-Q · filed 2023-08-02 |
| 2023-03-31 | $404.06M 10-Q · filed 2023-05-05 |
| 2022-12-31 | $440.97M 10-K · filed 2024-02-28 |
| 2022-09-30 | $482.75M 10-Q · filed 2022-11-02 |
| 2022-06-30 | $531.01M 10-Q · filed 2022-08-03 |
| 2022-03-31 | $568.92M 10-Q · filed 2022-05-04 |
| 2021-12-31 | $620.41M 10-K · filed 2023-02-22 |
| 2021-09-30 | $657.10M 10-Q · filed 2021-11-09 |
| 2021-06-30 | $698.21M 10-Q · filed 2021-08-05 |
| 2021-03-31 | $723.30M 10-Q · filed 2021-05-06 |
| 2020-12-31 | $511.82M 10-K · filed 2022-02-24 |
| 2020-09-30 | $528.23M 10-Q · filed 2020-11-06 |
| 2018-12-31 | $372.41M 10-K · filed 2019-03-01 |
| 2018-09-30 | $341.00M 10-Q · filed 2018-11-08 |
| 2018-06-30 | $347.50M 10-Q · filed 2018-08-07 |
| 2018-03-31 | $358.62M 10-Q · filed 2018-05-04 |
| 2017-12-31 | $329.21M 10-K · filed 2019-03-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B | |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B | |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |
| Tectonic Therapeutic, Inc. (TECX) | United States | $0.469B | -7.68 |
| C4 Therapeutics, Inc. (CCCC) | United States | $0.373B | -5.65 |
| FENNEC PHARMACEUTICALS INC. (FENC) | United States | $0.371B | -115.85 |
| REGENXBIO Inc. (RGNX) | United States | $0.477B | -3.30 |